Review Article
Year: 2023 | Month: March | Volume: 10 | Issue: 3 | Pages: 289-295
DOI: https://doi.org/10.52403/ijrr.20230333
Endometrial Hyperplasia as an Endometrial Cancer Risk Factor: Review Article
Ervina Pratiwi
Tiom Regional General Hospital, Lanny Jaya Regency, Tiom-Papua, Indonesia
Faculty of Medicine, University of HKBP Nommensen Medan-Indonesia
Corresponding Author: XYZ
ABSTRACT
The most prevalent cancer of the female reproductive tract in developed nations is Endometrial carcinoma (EC), preceded by endometrial hyperplasia (EH). EH is a non-invasive, abnormal growth of the uterine endometrial lining that carries a high risk of developing into EC or progressing to it. Premenopausal women's bleeding problems and postmenopausal women's vaginal bleeding are EH's main signs and symptoms. Chronic exposure to unopposed estrogen is the leading risk factor for the development of EH. Clinical management can range from monitoring to progestin therapy to a hysterectomy, depending on the risk of EC progression or concomitant EC and the patient's desire to maintain fertility. According to several studies, progestins effectively treat both benign and atypical EH. Endometrial cancer is relatively understudied compared to other malignancies with greater public awareness, such as ovarian and cervical. Therefore, in this review, we discuss Endometrial Hyperplasia as a risk factor an Endometrial Cancer
Keywords: Endometrial hyperplasia, Endometrial cancer, Progestins effectively
[PDF Full Text]